Researchers have found that a novel antibiotic, called zosurabalpin, effectively combats the drug-resistant bacteria Acinetobacter baumannii (CRAB). The new drug addresses serious infections in various body parts caused by the priority 1 pathogen.
This discovery is discussed in full in the study, titled "A novel antibiotic class targeting the lipopolysaccharide transporter" published in Nature, offering a promising solution against this superbug.
CRAB: A Growing Threat in Healthcare
The World Health Organization (WHO) classifies CRAB as a "priority 1" pathogen, reflecting its increasing prevalence in healthcare facilities. This resilient bacterium is responsible for severe infections, leading to a mortality rate of up to 60%. Commonly afflicting the urinary tract, respiratory system, and bloodstream, CRAB poses a significant threat, constituting approximately 20% of infections in healthcare settings.
Traditional antibiotics function by penetrating the cell wall of infectious bacteria, accessing crucial internal machinery to impede growth or induce cell death. However, CRAB presents a unique challenge with its double-layered cell wall, a characteristic identified as "gram-negative" by microbiologists.
This necessitates antibiotics to traverse both layers to effectively reach the vital machinery and combat the infection, unlike the usual process. Penicillin-based antibiotics, specifically carbapenems, designed 48 years after the discovery of penicillin, remain an exception to this rule.
While they operate by targeting the cell wall itself, these antibiotics have undergone strategic chemical modifications to thwart bacterial evolution and resistance. This modification has preserved their effectiveness and established them as crucial components in treating infections caused by Acinetobacter baumannii.
Despite the success of carbapenems, the superbug variant CRAB has evolved to dismantle these antibiotics, gaining an evolutionary advantage. This adaptability has propelled CRAB to a dominant position in hospitals, posing a formidable challenge in healthcare settings.
Zosurabalpin: A Breakthrough Antibiotic Against Resilient CRAB Infection
Zosurabalpin, an innovative antibiotic, has demonstrated potent efficacy against the antibiotic-resistant bacterium CRAB in both laboratory experiments and trials with infected animals.
The extensive testing involved over 100 CRAB samples from infected patients, with zosurabalpin successfully eradicating all bacterial strains. In mice with CRAB-infected bloodstream, the antibiotic not only prevented the development of sepsis but also showcased its ability to combat the resilient superbug.
The mechanism of action for zosurabalpin involves disrupting CRAB's defensive strategy by impeding the molecular machine LptB2FGC, responsible for transporting the toxin lipopolysaccharide. By inhibiting this process, zosurabalpin induces the toxin to accumulate within the bacteria, ultimately leading to the death of CRAB cells.
Notably, this unique mechanism, specific to CRAB, offers a promising avenue in microbiology, presenting a novel approach to tackling bacterial threats.
Currently undergoing phase 1 clinical trials, zosurabalpin is being rigorously tested to assess its effectiveness and potential side effects in humans. The exclusive targeting of CRAB infections by this antibiotic not only reduces the likelihood of antibiotic resistance but also marks a significant advancement in the ongoing battle against infections that defy conventional treatments.
Even with the challenges in developing antibiotics, the discovery of zosurabalpin presents a beacon of hope and considerable opportunities for scientific progress in the realm of combating antibiotic-resistant infections.
RELATED ARTICLE: Antibiotics With Modified Peptides Could Help Tackle Drug-Resistant Bacteria
Check out more news and information on Antibiotic Resistance in Science Times.
